Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
A.V. Kroll
San Diego, California, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Cellics Therapeutics is a clinical-stage biotechnology company developing a platform that coats synthetic nanoparticle cores with natural cell membranes (e.g., from red blood cells or macrophages). Its lead candidate, CT-01 (RBC-coated), is in Phase 1 clinical trials for MRSA pneumonia. Pre-clinical results have demonstrated the platform's ability to neutralize bacterial toxins and inflammatory cytokines.
- Therapeutic areas
- ImmunologyCardiovascularInfectious DiseasesRheumatologyOncology
- Modalities
- Cell membrane-coated nanoparticlesBiomimetic nanotechnologyNanoparticles
- Industry
- Academic Hospital/University/Research
Beyond the preview
Go deeper on A.V. Kroll.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on A.V. Kroll.